Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 27, 2019 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA

SOLANA BEACH, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
May 08, 2019 16:05 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports First Quarter 2019 Financial Results

Projected cash runway extended to first quarter 2020 SOLANA BEACH, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on...
April 02, 2019 06:00 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA

SOLANA BEACH, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
March 14, 2019 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA

SOLANA BEACH, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
March 06, 2019 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication

Recently received multi-disciplinary review (DR) letter from U.S. Food and Drug Administration (FDA) for Gimoti™ 505(b)(2) New Drug Application (NDA)April 1, 2019 Prescription Drug User Fee Act...
March 04, 2019 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Receives Preliminary FDA Communication on Gimoti™ NDA

SOLANA BEACH Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), today announced the receipt of a multi-disciplinary review (DR) letter from the U.S. Food and Drug...
February 27, 2019 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

SOLANA BEACH, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
January 07, 2019 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners

Novos to provide fully integrated commercial function for Evoke and non-dilutive financing for the commercialization of Gimoti, extending cash runway into 2020 Evoke will retain greater than 80% of...
November 13, 2018 16:05 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Third Quarter 2018 Results

April 1, 2019 PDUFA date for Gimoti™ NDA Cash runway extended through June 2019 SOLANA BEACH, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty...
August 16, 2018 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma’s Gimoti™ NDA Accepted for FDA Review

April 1, 2019 PDUFA Target Goal Date Gimoti Brand Name Conditionally Accepted SOLANA BEACH, Calif., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty...